Nantes, France–(Newsfile Corp. – February 6, 2025) – InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress Response (ISR) for a spectrum of neurological diseases, today announced the successful completion of its P288ALS TRIAL study (NCT05508074). This study was designed as a randomized, double-blind, …
Read More »
Matribhumi Samachar English